Femasys Jumps Almost 30% as Nasdaq Deadline Remains
Femasys Inc. shares rallied about 30% on Friday, a late-session pop for the women’s health stock as U.S. small caps pushed higher heading into Memorial Day weekend.
Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?
Femasys Inc. is a Georgia-based medical device and biotherapeutics company specializing in women’s reproductive health solutions. Founded and led by CEO Kathy Lee-Sepsick, Femasys aims to “transform women’s healthcare” by addressing long-neglected needs with non-surgical, in-office technologiesfemasys.comgurufocus.com. The company’s mission is to provide women with minimally invasive, office-based alternatives that improve patient care and reduce costs, in areas ranging from infertility to contraception and cancer diagnosticsfemasys.comgurufocus.com. Safety and accessibility are emphasized – Femasys notes that advances in female reproductive health are “long overdue,” and its products are designed to be used without general anesthesia or hospital infrastructureglobenewswire.cominvesting.com.
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?
Femasys stock has been on a rollercoaster ride in recent sessions. As of October 17, 2025, FEMY traded around the mid-$0.70s per share – more than double its price just a few weeks prior, and well off its 52-week low near $0.31 ts2.tech. On October 16, the stock spiked dramatically: opening near $0.55, it rallied to an intraday high of $0.84 before settling at $0.745 by the close finance.yahoo.com. This explosive move came amid unusually heavy volume stockinvest.us, indicating heightened investor interest.
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones
Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine inseminationglobenewswire.comstocktitan.net. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgeryir.femasys.comir.femasys.com.